Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Targin® Provides Patients With Cancer Pain Superior Bowel Function Without Compromising Analgesic Efficacy[1]


News provided by

Mundipharma

20 Sep, 2011, 23:01 GMT

Share this article

Share toX

Share this article

Share toX

CAMBRIDGE, England, September 21, 2011 /PRNewswire/ --

New research demonstrates oxycodone/naloxone prolonged-release tablets superiority compared with oxycodone prolonged-release tablets[1]

Treatment with Targin®(oxycodone/naloxone) prolonged-release tablets provides superior bowel function without compromising analgesic efficacy or safety when compared with oxycodone prolonged-release tablets alone in adult patients with moderate to severe cancer pain, according to new data published online today in Palliative Medicine[1].

This was a 4-week, randomised, double-blind, active-controlled, double-dummy, parallel-group study designed to evaluate the safety and efficacy of oxycodone/naloxone prolonged-release tabletsin 185 adult patients with moderate to severe chronic cancer pain[1].

Improvement in bowel function

The study shows an improvement in bowel function, as measured by the validated Bowel Function Index (BFI), after 4-weeks of treatment in those patients taking oxycodone/naloxone, with a statistically significant difference in the change from baseline in BFI score (∆BFI) between groups (∆BFI = -11.14; 95% confidence interval [CI]: -19.03, -3.24; p?0.01)[1]. At the same time, the mean total laxative (bisacodyl) intake was 20% lower in the oxycodone/naloxone group (26.10 [27.60] versus 32.69 [31.26] mg respectively; p=0.17)[1].

Over 4 weeks of treatment, Patient Assessment of Constipation Symptoms (PAC-SYM) scores improved in both groups, and the degree of improvement after four weeks was significantly greater for those taking oxycodone/naloxone than for those on oxycodone in terms of total symptom score (p=0.014) and frequency of symptoms (p<0.01)[1].

Analgesic efficacy and tolerability preserved

The mean level of pain control, as determined by the Brief Pain Inventory-Short Form (BPI-SF) scores, was similar for both treatments (3.50 [1.88] and 3.52 [1.80]) after 4 weeks, and the average rate of analgesic rescue medication use was low and comparable[1]. QoL assessments were stable and comparable with greater improvements in constipation-specific QoL assessments with oxycodone/naloxone than oxycodone, and rates of adverse drug reactions were similar in both treatment groups (38.0% versus 34.8%, respectively)[1].

"Many patients with cancer pain need to take strong analgesics, and oxycodone is now one of the established choices we have available," commented Professor Sam H Ahmedzai, University of Sheffield, UK.  "However, like other opioids, it can cause constipation.  Previous research has shown that the combination of oxycodone with the antagonist naloxone to counteract constipation, worked in patients with severe chronic, non-cancer pain.  This new study has shown for the first time that not only is oxycodone/naloxone a reliable analgesic in cancer patients, but it also significantly improves their bowel function. Targin® is therefore a major step forward in patient-friendly pain control."

Notes to Editors:

About the study

This was a randomised, double-blind, active-controlled, double-dummy, parallel-group, Phase II study in which 185 patients were randomised to receive up to 120/60 mg/day of oxycodone/naloxone prolonged-release tablets or up to 120 mg/day oxycodone prolonged-release tablets over 4 weeks, designed to evaluate the safety and efficacy of oxycodone/naloxone prolonged-release tablets in adult patients with moderate to severe chronic cancer pain.  Please note that Targin® is licensed for a maximum daily dose of 80/40mg[2]. Efficacy assessments included the Bowel Function Index (BFI), Brief Pain Inventory short form (BPI-SF), laxative and rescue medication use. Quality of life and safety assessments were conducted.

Bowel Function Index (BFI) is a validated clinician administered, patient reported, three-item questionnaire to assess patient-reported constipation-related symptoms ("ease of defecation", "feeling of incomplete bowel evacuation" and "patient judgment of constipation") rated on a numerical analogue scale between 0-100[3].

The Brief Pain Inventory Short Form (BPI-SF) is a validated, widely used, self-administered questionnaire developed to assess the severity of pain and the impact of pain on daily functions[4].

About Targin®

Targin® is a combination of the opioid analgesic oxycodone and the opioid receptor antagonist naloxone in a prolonged-release tablet formulation providing twice-daily dosing.

Targin® is licensed for the treatment of severe pain and to counteract opioid-induced constipation, and is marketed across Europe under the brand names Targin®, ▼Targinact®andTarginiq®.

About Mundipharma International Limited

The Mundipharma/Napp/Norpharma independent associated companies are privately owned companies and joint ventures covering the world's pharmaceutical markets. The companies worldwide are dedicated to bringing to patients with severe and debilitating diseases the benefits of novel treatment options in fields such as severe pain, haemato-oncology and respiratory disease. Prolonged release oxycodone / naloxone was developed by Mundipharma Research. For more information: http://www.mundipharma.co.uk

1. Ahmedzai, S. H., Nauck, F., Bar-Sela, G, et al. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe chronic cancer pain. Palliative Medicine, September 2011.

2. Targin SmPc.  Available at: http://www.medicines.ie/medicine/14383/SPC/Targin+5+2.5mg%2c+10mg+5mg%2c+20mg+10mg+and+40+20mg+prolonged+release+tablets/ [http://www.medicines.ie/medicine/14383/SPC/Targin+5+2.5mg%2c+10mg+5mg%2c+20mg+10mg+and+40+20mg+prolonged+release+tablets ]

3. Rentz AM, van Hanswijck de Jonge P, Leyendecker P, et al. Observational, Noninterventional, Multicentre Study for Validation of the Bowel Function Index for Constipation in European Countries. CMRO 2011;27(1):35-44.

4. Mendoza T, Mayne T, Rublee D, et al. Reliability and validity of a modified Brief Pain Inventory short form in patients with osteoarthritis. Eur J Pain 2006; 10: 353-61

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.